Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Additionally, in July 2023, Checkpoint announced longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC demonstrating a deepening of response over time, resulting in higher complete response rates than previously reported (55% objective response rate; 26% complete response rate in locally advanced cSCC and 50% objective response rate; 13% complete response rate in metastatic cSCC). Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncolog ...